Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early Triple-negative Breast Cancer (TNBC). An Open-label Randomized Two-cohort Phase 2 Clinical Trial. INVINCIBLE-4-SAKK

Next Previous
Trial Profile

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early Triple-negative Breast Cancer (TNBC). An Open-label Randomized Two-cohort Phase 2 Clinical Trial. INVINCIBLE-4-SAKK

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin/vinblastine (Primary) ; Anthracyclines; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel; Pembrolizumab
  • Indications Early breast cancer; Triple negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms INVINCIBLE-4
  • Sponsors Intensity Therapeutics

Most Recent Events

  • 11 Jun 2025 Results presented in the Intensity TherapeuticsMedia Release.
  • 11 Jun 2025 According to an Intensity Therapeutics media release, the company announces announces first few patients receiving INT230-6 achieved high levels of necrosis after 8 days in the Phase 2, INVINCIBLE-4 study, before they initiated the standard-of-care regimen
  • 11 Jun 2025 According to an Intensity Therapeutics media release, the company announces proposed public offering of common stock, The Company intends to use the net proceeds from the offering for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study, for the treatment of existing patients enrolled in the INVINCIBLE-3 Study, and for working capital and general corporate purposes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top